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Abstract
Continuous glucose monitors (CGM) record interstitial glucose levels ‘continuously’, pro-
ducing a sequence of measurements for each participant (e.g. the average glucose level
every 5 min over several days, both day and night). To analyse these data, researchers
tend to derive summary variables such as the area under the curve (AUC), to then use in
subsequent analyses. To date, a lack of consistency and transparency of precise defini-
tions used for these summary variables has hindered interpretation, replication and com-
parison of results across studies. We present GLU, an open-source software package for
deriving a consistent set of summary variables from CGM data. GLU performs quality
control of each CGM sample (e.g. addressing missing data), derives a diverse set of
summary variables (e.g. AUC and proportion of time spent in hypo-, normo- and hyper-
glycaemic levels) covering six broad domains, and outputs these (with quality control in-
formation) to the user. GLU is implemented in R and is available on GitHub at https://
github.com/MRCIEU/GLU. Git tag v0.2 corresponds to the version presented here.
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Introduction
Epidemiological and clinical studies interested in circulat-
ing glucose as a risk factor or outcome typically measure
levels in the blood (fasting, non-fasting and/or post-oral
glucose) at a single or widely spaced time-points (e.g. every
few years).1–4 Although these are important health
indicators, there has been an increasing appreciation that
glucose levels and variability in free-living conditions dur-
ing both the day and night, may also provide important
health measures in clinical (e.g. diabetic or obese) and
‘healthy’ populations.5–11 Continuous glucose monitoring
(CGM) systems measure interstitial glucose levels by
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implanting a sensor subcutaneously.12 Typically, finger
prick blood glucose measurements are needed to calibrate
the interstitial glucose levels to capillary blood glucose lev-
els, although devices that do not need this calibration step
are now becoming increasingly available.12,13 Throughout
this paper we refer to the sensor predicted capillary glucose
levels as ‘sensor glucose’.
CGM systems were initially used in research evaluating
their potential value in patients with diabetes.8,9,11–19 For
instance, some studies have assessed the accuracy of CGM
as a proxy measure of blood glucose,13,14,18 whereas others
have assessed the effectiveness of CGM in the management
of type I or type II diabetes.11,15,16,19 As a result CGM is
now increasingly used in the management of type I and
type II diabetes.20,21 More recently, CGM has been used in
a wider range of epidemiological studies, where the aim is
to understand the relationship of characteristics in these
CGM data with other health traits and disease. For in-
stance, CGM has been used to measure glucose levels
‘continuously’ over a number of days to identify hypo-
glycaemia in those receiving intensive care, and in ‘healthy’
populations to explore whether it can be used to identify
groups at increased risk of diabetes, including gestational
diabetes.22–26 Unlike the glucose level at a single time-point
providing only a ‘snap-shot’ of glycaemic control, or gly-
cated haemoglobin that gives a single measure indicating
mean glucose levels over a period of weeks, researchers can
use these CGM data to assess how interstitial glucose levels
vary across the day and night for several days or weeks and
identify determinants of this variation and its health im-
pact.22–26
Researchers using CGM data tend to first derive sum-
mary variables that are then used in their subsequent anal-
yses (e.g. exploring the association of these summary
variables with later health outcomes). Summary variables
might include area under the curve (AUC) (i.e. the average
glucose level over time) or time spent in low, medium or
high levels. Although there are a set of variables that may
be commonly derived in CGM studies there are increasing
examples of studies addressing broadly similar research
questions but deriving different summary variables. For
example, we found two papers assessing glycaemic vari-
ability in non-diabetic people, one that included morbidly
obese participants22 and the other that included healthy
people.27 Whilst both of these studies used standard devia-
tion (SD), coefficient of variation (CV) and mean ampli-
tude of glycaemic excursions (MAGE) as measures of
variability, the one in morbidly obese people also used
mean of daily differences (MODD)22 and the other used
mean absolute rate of change (MARC).27 These two stud-
ies illustrate that (i) several measures of variability can be
derived from CGM data and it is important to justify
which are used and differences between them, which nei-
ther of these papers did, and (ii) we would want consistent
measures to be used across studies. Even when different
studies derive a variable representing the same fundamen-
tal property it may be defined differently, e.g. using
different thresholds to define hypo-, normo- and hyper-
glycaemia.5,22 This lack of consistency across studies, to-
gether with insufficient reporting of study methods, means
that it is difficult to interpret results. It is also difficult to
seek replication or pool study results in meta-analyses
when varied measures are derived.5–8,11,28–30 For example,
a recent review that compared studies according to the
proportion of time in hypo- normo- and hyper-glycaemia
was limited because researchers used different thresholds
or did not include these measures at all.22 It is also unclear
whether researchers derive many summary variables but
only present those for which analysis supports their hy-
pothesis, such that the evidence published in the literature
and on which clinical decisions are based may be biased.31
The American Diabetes Association recently suggested
some summary statistics [such as the CV to assess variabil-
ity and proportion of time in ranges (hypo-, normo- and
hyper- glycaemia)] to assess glucose control in patients
with diabetes, but acknowledged further research was
needed to establish which summary measures are most
useful even in diabetes patients.8 Outside this guidance we
are unaware of any that has been suggested for the
broader use of CGM in epidemiology; nor are we aware of
any general epidemiology research tools to systematize
analyses of CGM data.
In this paper, we present GLU, a general open-
source software package for processing CGM data, for use
by researchers wishing to assess the relationship of charac-
teristics in CGM data with other traits and disease, using
data from any study design, including prospective cohort
studies or randomized trials, of general or clinical popula-
tions. The widespread use of this software across different
research studies will help to identify the key measurements
from CGM that have most clinical relevance in different
contexts and groups of patients, and in time potentially re-
sult in the most efficient and effective use of CGM in clini-
cal practice. GLU performs quality control and derives a
set of glucose characteristics (illustrated in Figure 1), that
can be used in subsequent analyses. Use of a common tool
will help to standardize methods across research studies.
Hence, in the future it will be easier to compare and meta-
analyse results across studies, and perform replication
analyses. An open source tool also improves transparency
of methods as all code is freely available, aiding interpreta-
tion of results. Furthermore, we intend to update GLU as
methods advance. The presentation of this tool is timely as
CGM is beginning to be widely adopted in epidemiological
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research, including both observational studies and ran-
domized controlled trials.22–26
Implementation
GLU is implemented in R and requires the following R pack-
ages: optparse, ggplot2, stringr [see GitHub repository
(https://github.com/MRCIEU/GLU) for package versions].
GLU supports CGM data from the Medtronic iPro2,32
Abbott Freestyle Libre33 and Dexcom G634 CGM devices,
specified using the ‘device’ argument. GLU can be used with
CGM data from other devices by converting to a general for-
mat and specifying the device as ‘other’. GLU is run by speci-
fying two directories; the location of the CGM data files and
the location where derived data (e.g. summary variables and
plots) should be stored. The CGM data is processed in two
main stages: (ii) quality control, and (ii) deriving summary
variables (illustrated in Figure 1). GLU allows the user to
specify optional arguments, and these include:
• nightstart and daystart: specifies the start time of the
day-time and night-time periods within each day period
to accommodate different populations (e.g. an early bed-
time may be more appropriate for studies of children).
By default, night-time is between 11.00 pm and 6.30 am.
If other times are used then this should be reported.
• firstvalid and dayPeriodStartTime: specifies the start time
of each day period, either the time corresponding to a
participants first sensor glucose value (hence specific to each
participant), or the time specified in the dayPeriodStartTime
argument (hence the same across participants). By default
this is set to the night-time period start time.
• pregnancy and diabetes: indicates that the data pertains
to pregnant women or diabetic patients, respectively,
such that summary variables specific to these populations
are derived (i.e. the thresholds used to determine the
time spent in hypo-, normo- and hyper-glycaemia levels,
described in the ‘Deriving glucose summary variables’
section below). If neither of these options is selected sum-
mary variables are produced that assume participants are
from a ‘general population’ without selection for preg-
nancy or diabetes.
• impute: specifies that GLU should perform ‘approximal’
or ‘other day’ imputation, rather than restricting to
‘complete days’, as described in the ‘CGM data quality
control’ section below.
GLU generates a comma-separated value (CSV) file of
derived summary variables, which can be imported into
statistical software for analysis.
CGM data quality control
GLU performs quality control to help researchers ensure
the integrity of the data, consisting of three automated
steps: resampling, outlier identification and dealing with
Figure 1. Illustration of summary variables derived by GLU. Summary variables are generated for each night-time period, each day-time period and
each full day, as appropriate (see Supplementary Table 2). Our approximation of fasting glucose level is calculated using night-time sensor glucose
data only. sGVP is a measure of variability from one moment to the next, whereas MAD denotes overall variability of glucose values while treating
time-points as a set of unordered values. The 11 GLU summary variables cover six broad domains. Domain 1, overall glucose levels: AUC (average
per minute) (mmol/L). Domain 2, glycaemic excursions: proportion of time in hypo-glycaemia, proportion of time in normo-glycaemia, proportion of
time in hyper-glycaemia. Domain 3, overall variability (dispersion): MAD (mmol/L). Domain 4, variability from one moment to the next: sGVP (%).
Domain 5, fasting glucose: fasting glucose proxy measure (mmol/L). Domain 6, post-event levels: post-prandial time to peak, post-prandial 1-h AUC,
post-prandial 2-h AUC, post-exercise 1-h AUC, post-exercise 2-h AUC, post-medication 1-h AUC, post-medication 2-h AUC.
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missing data (illustrated in Supplementary Figure 1, avail-
able as Supplementary data at IJE online). GLU also pro-
vides plots for manual review of the CGM data after these
automated steps.
Resampling
We resample the sensor glucose values across each partici-
pant’s CGM sequence to 1-min intervals using linear inter-
polation (i.e. assuming a straight line between values at
adjacent time-points), to facilitate computation of sum-
mary variables. Given two adjacent time-points t1 and t2,
with sensor glucose values SG1 and SG2, respectively, lin-
ear interpolation estimates the glucose value of time-point
t
0
where t1  t0  t2 as:
SG
0 ¼ ð1 wÞ  SG1 þw SG2
where w ¼ t0  t1t2 t1.
Outlier detection
Previous work has suggested that outliers can be detected
by identifying time-points that are more than two standard
deviations (SD) from the sensor glucose values at both the
previous and subsequent time-points.5 However, as noted
previously,6,24,35 glucose levels may not be normally dis-
tributed, so SD may not be an appropriate measure of vari-
ability. Furthermore, this approach is sensitive to the
resolution of the glucose trace such that changes in resolu-
tion would affect which regions of a glucose trace are
marked as outliers. This is because SD is invariant to
changes in sampling frequency of a glucose trace, whereas
the difference in glucose levels between adjacent time-
points is not. For example, if sensor glucose is recorded ev-
ery 1 min rather than every 5 min then the difference in
glucose levels between adjacent time-points will be smaller
but the overall distribution of sensor glucose values, and
hence the outlier detection threshold (based on the SD of
this distribution), will not change.
Using data described in our usage example (see Usage
section below), we visually assessed the distribution of sen-
sor glucose values for each participant and found these dis-
tributions to be very variable—some were normally
distributed whereas others were skewed. We therefore base
our outlier detection on the distribution of the differences
of adjacent sensor glucose values rather than the distribu-
tion of sensor glucose values. We found that the distribu-
tions of the difference of adjacent sensor glucose values
were more consistently normally distributed compared
with the distributions of sensor glucose values. Also, using
the differences of adjacent values means that this approach
is invariant to changes in the resolution of a glucose trace.
We use a threshold d, of kSD of a participant’s distribu-
tion of differences between adjacent values.36 Time-points
with a glucose value that deviate more than d from the
value at both the previous and subsequent time-points, are
marked as outliers for further consideration by the re-
searcher. We chose a threshold of 5SD based on experi-
mentation with our example data (see Supplementary
Section S1, available as Supplementary data at IJE online
for further details). Users can also change the value of k us-
ing GLU’s outlierthreshold argument (see GLU GitHub re-
pository for details), to make the outlier detection more
conservative or lenient. Should outliers be detected and
confirmed by visual inspection of the glucose trace then
researchers may wish to: (i) use other data such as diet dia-
ries to determine whether detected outliers may be due to
some underlying cause such as food intake (rather than er-
roneous), and (ii) perform sensitivity analyses to see the ef-
fect that removing identified outliers has on their results.
Our outlier detection method uses a threshold determined
using artificial outliers because we have no CGM data con-
taining clear (erroneous) outliers on which to base our ap-
proach (Supplementary Section S1, available as
Supplementary data at IJE online). As CGM becomes
more widely used, it will be possible to improve detection
of outliers using outlier examples, and we plan to update
GLU outlier detection as the field matures.
Assessing the impact of missing data
assumptions
CGM data may have missing time periods when the de-
vice is unable to record an interstitial glucose value, for
example, if the device becomes displaced. When missing
periods do exist, there may be systematic differences be-
tween the missing and observed values in the CGM data,
such that the derived GLU summary variables may be bi-
ased. For instance, if sensor displacement (or removal)
occurs during swimming and swimming is associated with
low glucose values, then a swimmer’s average glucose lev-
els estimated using the observed data may be higher com-
pared with the true underlying value. Under those
circumstances associations of the GLU summary variables
with a potential outcome or a risk factor may be biased.
Alternatively, the CGM missing time periods may be
missing completely at random—for instance, some tech-
nological failures of CGM devices may be due to chance.
We note that there are two related but distinct biases
when using GLU-derived summary variables: (i) bias of
the derived values of participants GLU summary varia-
bles, and (ii) bias in subsequent analyses using these sum-
mary variables. Bias from the former does not necessarily
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cause bias for the latter as this depends on the specific
analyses performed.
GLU provides three approaches to help address missing
data called ‘complete days’, ‘approximal imputed’ and
‘other day imputed’, that make different missingness
assumptions. GLU’s complete days approach uses only
days with complete sensor glucose values to derive glucose
characteristics [e.g. 24 (h) x 60/5¼ 288 values when using
CGM data with 5 min intervals]. If the days of CGM data
are missing completely at random (MCARdays) such that
there are no systematic differences between the days with
and without missing CGM data, then the derived CGM
statistics will be unbiased, hence this missingness will not
bias results of subsequent analyses.37 The MCARdays as-
sumption of the ‘complete days’ approach may be violated.
For example, characteristics of the participants such as
their age or employment status may influence whether or
not they complete the required number of capillary blood
tests or the likelihood of the CGM device being displaced.
However, even when MCARdays does not hold, analyses
using GLU’s complete days statistics may still be unbiased
depending on the specific further analysis in which they are
used.37
In general, imputation may help to reduce the amount
of excluded data and relax the missing data assumptions,
such that missing at random (MAR) [or sometimes missing
not at random (MNAR)] may be assumed rather than
MCAR.37 However, glycaemic control is influenced by
several characteristics such that imputing portions of a glu-
cose trace is non-trivial.
GLU includes two simple imputation approaches that
fill in the missing periods using non-missing regions of a
participant’s data. We refer to these approaches as
‘approximal imputation’ and ‘other day imputation’, and
both require that a day has at most 6 h missing data to be
considered for imputation. The approximal imputation ap-
proach fills in the missing periods using non-missing
regions near to the missing region, within the same day.
This approach splits the missing period in half, and uses
the sensor glucose data on the left to fill in the left half,
and the sensor glucose data on the right to fill in the right
half, as illustrated in Supplementary Figure 2, available as
Supplementary data at IJE online. Formally, given a miss-
ing period of sensor glucose values fSGi, SGiþ1 . . . SGj1,
SGjg, fSGi . . . SGkg is replaced with fSG2ik1 . . . SGi1g
and fSGk’ . . . SGjg is replaced with fSGjþ1 . . . SG2jþ1k0g,
where k¼iþfloor((jiþ1)/2)-1 and k0¼kþ 1 are the end
start indexes of the first and second halves of this missing
period, respectively. Each missing sequence must be less
than 2 h long to be considered for imputation.
The ‘other day imputation’ approach fills in the missing
periods using data from the same time period on a different
day of the same participant’s data. For each missing pe-
riod, this approach first identifies all days for this partici-
pant where the same time period has complete data. GLU
then randomly selects one of these days and then replaces
the missing period with this day’s time-matched data. For
both the approximal and other day imputation approaches
the imputed data is labelled such that the transitions be-
tween non-imputed and imputed sections (and transitions
between the left and right halves of imputed sections for
the approximal imputation approach), are not incorpo-
rated into summary variables—i.e. only transitions within
sections are incorporated (see Supplementary Figure 2).
Approximal and other day imputation may help to re-
duce bias in the derived CGM statistics and hence bias in
subsequent analyses that use these statistics. Under the as-
sumption that the region used to impute each missing pe-
riod is representative of that particular missing period,
then CGM statistics derived from imputed data may be
less biased. In particular, the approximal approach
assumes nearby time periods on the same day are represen-
tative of the missing period, whereas the other day ap-
proach assumes that glucose patterns over a 24 h period
are broadly similar such that regions at the same time on
alternate days are representative of the missing period. It
may however be more likely that missing regions are sys-
tematically different to the non-missing regions used for
the imputation. For example, if a device is unable to record
very high glucose values then the non-missing glucose val-
ues used to impute the missing region will be systematically
lower. In this case approximal or other day imputation
may still help to reduce bias in the derived CGM statistics.
This is because, if days with missing data are systematically
different to days without missing data then approximal im-
putation will enable information from (the non-missing
time periods on) these systematically different days to be
incorporated into the derived summary variables.
Similarly, if the CGM data are MCARday (i.e. the days of
CGM data are MCAR as described above) then the sum-
mary variables derived using approximal or other day im-
puted data will be unbiased and more precise than the
complete days version.
By default, GLU uses the complete days approach.
Users can use the approximal or other day imputation
approaches by running GLU with the imputeApproximal
or imputeOtherDay arguments, respectively. A researcher
wishing to apply another imputation approach to their
data (e.g. mean imputation, if appropriate) can do this
prior to running GLU. In the rest of this paper we refer to
days with complete CGM sequences (after imputation if
this option is used) as the set of included days. We would
suggest that researchers run their analyses using both com-
plete days and imputed data (both approximal and other
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day versions) and present all results from further analyses
so that over time we can learn more about the nature of
CGM missing data and its impact on different research
questions. It is important to note that these are ‘simple’ im-
putation approaches that fill in missing data prior to any
analyses, such that standard errors in subsequent analyses
using these imputed data may be underestimated.
Manual review
In the Data visualization section we describe two plots gen-
erated by GLU; these can be used to further check data va-
lidity (see Usage section for a description of how we do
this in our example).
Deriving glucose summary variables
After quality control, GLU derives a set of summary varia-
bles illustrated in Figure 1. A full list of summary variables
computed by GLU is given in Supplementary Table 2,
available as Supplementary data at IJE online. Each char-
acteristic is calculated for each day in a participant’s CGM
data and, where appropriate, the day-time and night-time
separately (see Supplementary Table 2).8 GLU also pro-
vides the average of each summary variable across all days
for each participant to give a single overall value for each
summary variable (for each participant). For example,
GLU returns the following AUC statistics: (i) AUC for each
included day (24 h), (ii) AUC for each included day for the
night-time period, (iii) AUC for each included day for the
day-time period, (iv) mean AUC over all included days
(based on a 24-h day), (v) mean AUC of night-time periods
over all included days, and (vi) mean AUC of day-time
periods over all included days. The daily statistics provided
by GLU allow variability both between and within days to
be assessed.
Glucose summary variables output by GLU were chosen
to represent broad categories of glucose characteristics that
reflect a set of six broad domains that might, indepen-
dently of each other, relate to outcomes or be influenced
by exposures (including interventions in randomized con-
trolled trials). Supplementary Table 1, available as
Supplementary data at IJE online, lists these variables, to-
gether with other variables that have been included in
some publications but are not included here (together with
our reasons for not including them). The six broad
domains are: overall glucose levels, overall variability (dis-
persion), excursions (deviations from ‘normal’), variability
from one moment to the next, fasting levels and post-event
levels. GLU includes one variable from each domain and
brief explanations for these choices are given in
Supplementary Table 1. For example, we considered three
measures of dispersion that have been used in previous
publications—SD, CV and median absolute deviation
(MAD); GLU includes only MAD. This is because sensor
glucose values may not be normally distributed and the
number of sensor glucose values across which GLU will
calculate dispersion will be low (e.g. 1 day contains 288
values for 5 min epochs), meaning that SD and CV are un-
likely to be credible measures of dispersion. All GLU sum-
mary variables are independent of the length of the time
period for which they are calculated.
Overall glucose levels
Overall glucose levels are characterized by the AUC, and
specifically GLU derives the mean AUC per minute so that
these levels are comparable across time periods of different
lengths (e.g. night-time vs day-time).8 For each day, the
AUC is calculated using the trapezoid method,5 as the sum
of the area of the trapezoids created using linear interpola-
tion between sensor glucose values at adjacent time-points
(as described above). We divide by the number of minutes
in the time period (e.g. 1440 for whole days) to give the av-
erage glucose level (mmol/L) per min.
Proportion of time in hypo-, normo- and
hyper-glycaemia
We calculate the proportion of time spent in hypo-, normo-
and hyper-glycaemia.8,25,38 In patients with diabetes GLUs
default for hypo-glycaemia is <3.9mmol/L and for hyper-
glycaemia is 10.0 mmol/L (with normo-glycaemia defined
as 3.9mmol/L to <10 mmol/L).20,39 In a ‘healthy’ (non-di-
abetic) and non-pregnant population hypo-glycaemia is de-
fined as <3.3 mmol/L40 and we use the diabetes threshold
(10 mmol/L) to define hyper-glycaemia, such that normo-
glycaemia defined as 3.3 to <10 mmol/L. For ‘healthy’
(non-diabetic) pregnant women we use the recommended
targets of glucose control during pregnancy for both type 1
and type 2 diabetes of 3.5–7.8 mmol/L, such that hypo-
glycaemia is defined as <3.5mmol/L and hyper-glycaemia is
defined as 7.8 mmol/L.20 The 7.8 mmol/L threshold is also
consistent with other guidelines such as the UK National
Institute for Health and Care Excellence (NICE) 2-h post-
prandial threshold for diagnosing gestational diabetes.41 As
already described, these diabetic and pregnancy specific
thresholds can be specified using GLU’s diabetic and preg-
nancy arguments, respectively. Because thresholds for defin-
ing hypo- and hyper-glycaemia (in ‘healthy’, diabetic
and pregnant populations) vary geographically and over-
time,42–44 and differ for other groups (e.g. patients in inten-
sive care units25), GLU also allows users to specify other
thresholds. For instance, a study in a diabetic population may
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wish to use the <3.0 mmol/L hypo-glycaemia threshold rec-
ommended by the International Hypoglycaemia Study Group
for clinically significant biochemical hypo-glycaemia.44
However, since GLU is intended to provide standard meas-
ures that can be compared (and as appropriate pooled)
across studies, where researchers do this a clear justifica-
tion should be given.
Overall variability
Although SD and CV are widely used measures of glucose
variability,9,30 as discussed above, the distribution of sen-
sor glucose values for a given participant may not be nor-
mally distributed. For this reason we use the MAD as a
measure of overall variability of sensor glucose levels, de-
fined as:
MAD ¼ median jSGi  median SGð Þj
 
Thus, after calculating the distance of each sensor glucose
value from the median value, MAD is the median of these
distances.
Variability from one moment to the next
We capture variability in a person’s glucose levels across
time using a measure based on the length of the line of a
glucose trace (i.e. as if the peaks and troughs were
stretched out into a line). This idea was recently suggested
for CGM data45 and previously proposed as a measure
of complexity for time-series analyses in general.46
Intuitively, if you stretch out a glucose trace then the resul-
tant straight line will tend to be longer when a trace has
a larger overall variability (represented by MAD) and
is more complex (a higher number of peaks, valleys and
values46) see Supplementary Figure 3, available as
Supplementary data at IJE online and46 for examples. This
is distinct from MAD because, unlike MAD, the length of
the line is affected by the order of the sensor glucose val-
ues, i.e. how the sensor glucose values change from one
moment to the next (see Supplementary Figure 4, available
as Supplementary data at IJE online). Glycaemic variabil-
ity percentage (GVP)45 is a rescaling of the average length
of the line per minute such that a trace with no variability
(i.e. a constant trace) has a GVP of zero. A trace with a
GVP of 100% would imply that the length of the trace is
double the length of a straight glucose trace. We adapt this
measure to capture complexity but not overall variability
(in line with46), as overall variability is captured by MAD.
We standardize each glucose trace prior to deriving GVP
by subtracting the median and dividing by the MAD. We
refer to the GVP calculated using the standardized glucose
levels as standardized GVP (sGVP). Formally, sGVP is de-
fined as:
sGVP ¼ L
T Nð Þ  T 1ð Þ  1
 
 100
where
L ¼
XN1
i¼1
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðSGs ið Þ  SGs i þ 1ð ÞÞ2 þ ðT ið Þ  T i þ 1ð ÞÞ2
q
and T and SGs are vectors of timestamps and standardized
sensor glucose values, respectively, of length N.46 For ex-
ample, given a day period of CGM data after resampling
to 1 min epochs then T(10) and SGs(10) are the tenth min-
ute in this day and the standardized sensor glucose value
on this tenth minute, respectively.
This measure satisfies three useful properties: (i) invari-
ance to the intervals between time-points, (ii) invariance to
differences in overall variability and (iii) invariance to dif-
ferences in the duration of the CGM trace. The first prop-
erty is satisfied by using a measure based on the length of
the line (see Supplementary Figure 5a, available as
Supplementary data at IJE online) and means that results
of work using different intervals can be compared or meta-
analysed. The second property is satisfied by standardizing
the CGM trace before calculating GVP (see Supplementary
Figure 5b, available as Supplementary data at IJE online)
and means that associations with sGVP are not due to a re-
lationship with overall variability (i.e. MAD). The third
property is satisfied by dividing by the total duration in the
above equation (see Supplementary Figure 5c, available as
Supplementary data at IJE online) and means that variabil-
ity from one moment to the next can be compared across
time periods of different length.
Fasting glucose proxy
Although fasting glucose levels have previously been ap-
proximated using CGM data, the methods used to derive
this measure can be unclear.47,48 In studies where meal
times are known, fasting glucose levels may be inferred us-
ing CGM data recorded before breakfast or after at least
7 h fasting,5,26,49 e.g. using the mean of the six consecutive
values (with 5 min intervals) before breakfast.26 Others
have used glucose levels during particular periods of the
night-time as fasting levels, when meal times are not
known.50 This can be problematic if participants eat dur-
ing the night-time period,5 which occurs in an important
minority who may be different in terms of their health and
health-related behaviours to those who do not eat during
the night.51 GLU derives a general proxy measure of fast-
ing glucose that does not require knowledge of meal times,
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calculated as the mean of the 30 lowest consecutive
minutes (equating to 6 CGM values at 5 min intervals) dur-
ing the night-time.
Event statistics
Studies may ask participants to report their meal times and
where this is the case GLU will generate three statistics de-
scribing subsequent glucose levels: time to peak, and glu-
cose levels 1- and 2-h post-prandial.5
Time to peak is calculated as the number of minutes from
the meal to the next peak in sensor glucose values—i.e. the
nearest subsequent sensor glucose value SGt at time t where
SGt1< SGt > SGt2, and t1 and t2 are the nearest previous
and subsequent time-points to t, respectively, where
SGt 6¼ SGt1 and SGt 6¼ SGt2. We cannot simply find the
time-point with a higher glucose value than the time-points
directly before and after, as the peak may consist of a plateau
where multiple time-points have the same value.
The 1-h and 2-h post-prandial glucose measures are cal-
culated as the AUC during the 15-min period 1- and 2-h,
respectively, after the meal was recorded. We also calculate
the 1- and 2-h AUC for exercise and medication events,
when this information is available. In addition to deriving
the average of these summary variables on each included
day, and across all included days, the saveevents argument
can be used to output the summary variables for each
event. This can be useful where the number of events
across days is highly variable such that averaging within
and across days may not be appropriate.
Data visualization
The following plots are produced by GLU.
• Sensor glucose trace plots for all participants that can be
visually inspected. This plot also includes indicators of
events (where these are provided) including the timing of
a meal, exercise, use of relevant medications and capil-
lary blood glucose measurement levels. Identified outlier
values and imputed time periods (as described above) are
also shown on these plots.
• Poincare plots to illustrate the stability of each partici-
pants blood glucose levels.10,35,38 Each point on a
Poincare plot is the sensor glucose level at time-point t
(on the x-axis) against the sensor glucose level at time-
point t þ 1 on the y-axis. Thus, where a participant’s
sensor glucose levels change slowly their Poincare plot
will be aligned along the ascending diagonal, but those
with erratic (and potentially erroneous) sensor glucose
levels will have a spread further from the ascending
diagonal.
Example sensor glucose trace plots and Poincare plots are
shown in Supplementary Figure 6, available as
Supplementary data at IJE online, and in the GLU GitHub
repository.
Usage
In this example, we demonstrate GLU by deriving GLU
summary variables from CGM data measured during preg-
nancy and postnatally, and exploring associations of body
mass index (BMI) with these variables during pregnancy.
Study sample
We used data from the Avon Longitudinal Study of Parents
and Children-Generation 2 (ALSPAC-G2).52 The ALSPAC
study website contains details of the data that are available
through a fully searchable data dictionary: http://www.
bris.ac.uk/alspac/researchers/data-access/data-dictionary/.
The original ALSPAC cohort (women recruited during an
index pregnancy in the early 1990s; ALSPAC-G0) and
their index children (ALSPAC-G1) have been described in
full elsewhere.1,2 ALSPAC-G2 refers to the children of
ALSPAC-G1 and recruitment to this cohort began in June
2012, and further information can be found at http://
www.alspac.bris.ac.uk. The data presented here come
from a pilot study of CGM in pregnant/postnatal women,
which began recruiting ALSPAC-G1 women (or female
partners of ALSPAC-G1 men) during their pregnancy in
February 2016. These women were invited to wear a
Medtronic iPro2 CGM on their buttock, abdomen or arm,
for 6 days, at up to four time-points: in early f<28 weeks
gestation [median¼ 21 weeks gestation, interquartile range
(IQR) ¼ (18, 23) range ¼ (6, 27)]g and late f28 weeks
gestation [median¼ 34 weeks gestation, IQR ¼ (32, 35)
range ¼ (28, 36)]g pregnancy, and 6- and 12-months
postnatal [median¼ 28 weeks, IQR ¼ (26, 31) and
median¼ 58 weeks, IQR ¼ (55, 63.5), respectively]. We re-
fer to the CGM data collected at a particular time-point
for a particular participant as a CGM instance. While
wearing the device, participants were asked to measure
their capillary blood glucose levels by finger prick four
times daily, for CGM calibration, and record mealtimes in
a hand-written diary.
In this pilot a total of 96 CGM instances had been col-
lected, in 63 women. Using GLU’s complete days ap-
proach, nine of the 96 instances were excluded due to
missing data (one recorded no sensor glucose data and
eight had no complete days). One participant has two early
pregnancy time-points corresponding to two different
pregnancies; we excluded the time-point for the later preg-
nancy. We also excluded one participant (with 1 time-
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point) who did not have a measure of BMI. Thus, our pilot
includes 85 CGM instances (including a total of 321 in-
cluded days)—29 in early pregnancy, 25 in late pregnancy,
15 at 6 months postnatal and 16 at 12 months postnatal.
These 85 instances were measured in 61 women. Imputing
the sensor glucose data using the approximal and other
day imputation approaches both resulted in an additional
2 CGM instances with at least 1 included day, for 2 addi-
tional participants. Our approximal imputed dataset
includes 87 CGM instances, with a total of 333 included
days, in 63 women. Our other day imputed dataset
includes 88 CGM instances, with a total of 357 included
days, in 63 women. Supplementary Table 3, available as
Supplementary data at IJE online, shows the patterns of re-
peat instances within our sample, using the complete days,
approximal imputation and other day imputation
approaches.
Women’s weight and height were measured at the clinic
visit when the CGM device was inserted and used to calcu-
late BMI (kg/m2). We considered age, parity and gesta-
tional age at CGM measurement as potential confounding
factors. Age and parity were reported by the woman; gesta-
tional age was calculated from the dates for which the
CGM was worn and the woman’s expected date of delivery
based on her antenatal records (for the vast majority this
would be based on a dating scan).
Analyses
Since GLU uses different thresholds for defining hypo-
normo- and hyper- glycaemia in pregnant compared with
non-pregnant women, we divided our CGM instances into
pregnancy and postnatal subsets. For the pregnancy subset,
we ran GLU with the pregnancy argument. For the postna-
tal subset, we used the default GLU settings (i.e. we did not
specify any optional parameters). For both, we ran GLU
with the complete days approach (which is used by de-
fault), and the approximal and other day imputation
approaches. We manually reviewed the trace and Poincare
plots to determine whether there may be any anomalies.
Poincare plots show how a person’s glucose levels vary
across moments in time (specifically one minute to the
next, because GLU resamples CGM data to 1-min intervals
as a pre-processing step). A deviation from the trend along
the ascending diagonal on this plot may reflect an errone-
ous sensor glucose value in the original CGM data, rather
than true variation of glucose levels. Sensor glucose values
will tend to vary smoothly on CGM trace plots so
erratic changes shown on these plots may also indicate er-
roneous data.
We summarized our derived GLU summary variables at
each of the two pregnancy and two postnatal time-points
using median and IQR. We then examined the association
between early pregnancy BMI (exposure) and GLU CGM-
derived variables during pregnancy, using the 43 women
with a measure during pregnancy. Of these 43 women 32
had just one set of CGM data during pregnancy (18 early-
and 14 late-pregnancy) and 11 had data for both early and
late pregnancy. For the main analyses we used late preg-
nancy data for the 11 participants with data at both preg-
nancy time-points. We also undertook a sensitivity analysis
in which we instead used early pregnancy measures for
these 11 participants. We used linear regression to estimate
the association of BMI with the following glucose trace
summary variables: overall mean glucose level, MAD,
sGVP, fasting glucose proxy, post-prandial time-to-peak
and post-prandial 1- and 2-h AUC. MAD, sGVP and post-
prandial time-to-peak were right skewed and hence log
transformed to achieve approximately normally distribu-
tions of residuals from the regression model. We converted
the proportion of time spent in hypo-, normo- and hyper-
glycaemia to the number of minutes, by multiplying these
by the number of minutes in the defined period (e.g. 1440
in whole days). We then estimated the association of BMI
with these outcomes using negative binomial regression.
Our analyses were performed using Stata version 15, and
code is available at https://github.com/MRCIEU/GLU-
UsageExample/. Git tag v0.2 corresponds to the version
presented here.
Results
In this pilot we did not identify any outlier time-points
having a glucose value with a large deviation from the glu-
cose values at previous or subsequent time-points
(Supplementary Figure 6 shows some representative trace
plots illustrating their smooth nature). Correlations be-
tween summary variables are given in Supplementary
Table 4, available as Supplementary data at IJE online.
The smallest correlation was between MAD and post-
prandial time to peak [Pearson’s r ¼ 0.005 (P¼ 0.98)],
whereas the largest was between proportion of time spent
in hypo- and normo- glycaemia [Pearson’s r ¼ 0.958
(P< 0.01)]. Our sample rarely reached hyper-glycaemic
glucose levels [e.g. median 0.000 (interquartile range:
0.000, 0.003) in early pregnancy; Supplementary Table 5,
available as Supplementary data at IJE online], such that
correlations between time spent in hypo-glycaemia and
normo-glycaemia were close to 1 (Supplementary Table
4). While GLU gives the sGVP summary variable,
Supplementary Table 4 also includes correlations with
GVP (that uses the unstandardized glucose trace) for com-
parison. MAD was positively correlated with GVP
[Pearson’s r¼ 0.86 (P<0.01)] and negatively correlated
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with sGVP [Pearson’s r ¼ 0.54 (P<0.01)]. We hypothe-
sized that this is because a glucose trace with a larger over-
all variability (characterized by MAD) will on average
have a lower frequency (intuitively the bigger the deviation
the longer it will take to return from this deviation) result-
ing in a shorter ‘length of the line’ of the glucose trace after
standardization. To check this, we derived a simple mea-
sure of the number of peaks in each trace and found this
had a negative correlation with MAD [Pearson’s r ¼ 0.24
(P¼ 0.13)]. Overall, sGVP was less correlated with other
GLU summary variables, compared with both MAD and
(unstandardized) GVP.
Overall mean glucose levels were very similar
(5 mmol/L) across the four time-points (Supplementary
Table 5). However, these similar overall glucose levels con-
ceal very different patterns of variation in glucose across
the four time-points and in the day- vs the night-time.
MAD values were higher during pregnancy (both early and
late) than postnatally, and higher during the day-time com-
pared with the night-time. Fasting glucose levels were, on
average, higher 12 months postnatally compared with early
pregnancy. Whereas most time was spent normo-glycaemic
both during pregnancy and in the postnatal period, the
amount of time spent with levels that fulfilled the criteria
for hypo-glycaemia was higher during pregnancy com-
pared with postnatally. In interpreting the proportion of
time spent in different glycaemic states across these four
time periods it is important to remember that we used the
pregnancy argument for the early and late pregnancy meas-
ures but the default (non-pregnancy, ‘healthy’) option for
the postnatal measures. Hence different thresholds were
used to define hypo-, normo- and hyper-glycaemic ranges
in pregnancy vs postnatally. It is possible that in some
women pregnancy-related changes in glucose levels might
persist postnatally, so we repeated the analyses with the
pregnancy function applied to the postnatal time-points.
The proportion of time spent in normo-glycaemia postna-
tally was lower when using the pregnancy argument, be-
cause the pregnancy target normo-glycaemia range is
narrower. Results were broadly similar when missing
data at some time-points were imputed using both the
approximal and other day approaches (Figure 2 and
Supplementary Table 6, available as Supplementary data
at IJE online).
In analyses using complete days, approximally imputed
and other day imputed data a higher BMI during preg-
nancy was associated with higher overall mean glucose lev-
els during both the day- and night-time (as measured by
AUC), higher time spent in hyper-glycaemia during the
night-time and shorter post-prandial time to peak, with
similar magnitude of association across the three different
approaches to missing data (Figure 2). For example, during
the night-time a 1 kg/m2 higher BMI was associated with a
0.024 mmol/L higher glucose level per min (95% confi-
dence interval: 0.004, 0.044), after adjusting for covariates
(age, parity and gestational age). A higher BMI during
pregnancy was associated with higher overall variability of
glucose levels during the night-time (as measured by
MAD), but we found little evidence of an association with
the trace complexity (as measured by sGVP) although this
may be due to insufficient statistical power. Results were
broadly consistent when we used the early pregnancy
measures for the 11 women with both early and late preg-
nancy results (Supplementary Figure 7, available as
Supplementary data at IJE online).
Conclusions
In this paper, we have presented GLU, an open-source tool
for researchers working with CGM data. GLU automati-
cally performs quality control and derives a set of summary
variables capturing key characteristics in these data.
Widespread use of this tool across different research popu-
lations will help to identify the key measurements from
CGM that have most clinical relevance in different con-
texts and groups of patients, which in turn will inform the
most efficient and effective use of CGM in clinical
practice.
There are other previously published tools for analysing
CGM data, and Supplementary Table 7, available as
Supplementary data at IJE online, provides a comparison
of these with GLU. Compared with each of these, GLU is
the only one to implement outlier detection. Also, GLU’s
quality control ensures that only whole days (either before
or after imputation) are included in analyses to minimize
bias. Our imputation methods seek to maintain the integ-
rity of the data where the imputed regions are realistic
CGM sequences (e.g. in contrast to linear interpolation).
While the recently published CGManalyzer tool has a dia-
betes focus,53 GLU is a general tool for researchers analy-
sing CGM data in any population. We have developed this
software so that it can be used to produce a standard set of
CGM summary variables in any population and study
type, including ‘healthy’ populations, whether pregnant or
not, as well as in studies of people with diabetes, in cohort,
case-control or randomized trials. Using a single tool for
research in these different populations will aid comparison
of summary variables and results across them. The
Glycemic Variability Analyzer Program (GVAP) tool54 is
implemented in MATLAB and, hence, requires a licence to
use, whereas GLU can be freely used by anyone. In con-
trast to GVAP, GLU can be used directly with CGM
data from several devices. Another tool called EasyGV is
implemented as a Microsoft Excel workbook;55 it is not
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open-source (i.e. it is not possible to view the macro code),
hindering research reproducibility, and the ‘point and
click’ interface means it is difficult to integrate program-
matically within a research pipeline. Systems provided by
CGM companies, such as the Medtronics Carelink iPro
website, also provide summary variables but using these
for research would hinder consistency across studies since
the summary variables and derivations used would depend
on the CGM device, and these are also not open-source,
hindering transparency.
In addition to the quality control steps implemented in
GLU, another key strength is our choice of summary varia-
bles, where these characteristics each represent one of six
broad domains. For example, overall glucose levels and
variability from one moment to the next are represented by
the AUC and sGVP, respectively. Our choice of summary
variable from each domain was informed by previous
work, interpretability of each variable, and the statistical
properties of CGM data. For example, given the skewed
nature of glucose data, GLU uses MAD as a measure of
spread, rather than the SD or CV (see Supplementary
Table 1).
Previously, there has been a lack of consensus in rela-
tion to the methods used to derive variables from CGM
data. Furthermore, methodological details have often
been missing from research articles, making it difficult to
replicate studies and compare results across studies.5,28
Therefore, our main aim was to improve research prac-
tice by providing an open-source software package for
CGM research, to improve transparency and consistency
across studies. Using GLU to perform CGM processing
and persuading researchers to present findings using all
of its summary measures (even if some are presented as
supplementary material) should improve the consistency
across studies and hence the opportunity for replication
and pooling of results, which is important for improving
the robustness of research in this field. Furthermore, over
time this would allow insights to emerge related to which
glucose trace properties are important for different popu-
lations and in relation to different exposures and out-
comes. For example, our pilot data suggest that, during
pregnancy, BMI is positively associated with mean glu-
cose levels, including during the day and night, as well as
time spent hyper-glycaemic and overall variability of glu-
cose levels during the night-time, but has little associa-
tion with complexity of the glucose trace. We
acknowledge that these are pilot data and for some of the
outcomes estimates are imprecise (with wide confidence
intervals). As larger CGM datasets become available it
will be possible to estimate associations with greater
Figure 2. Associations of BMI with GLU summary variables. Estimates using ‘complete days’, ‘approximal imputed’ and ‘other day’ imputed data,
after adjustment for covariates (age, parity and gestational age at CGM measurement). Estimates use the mean of the respective summary variable
across all included days. All AUC measures are computed as the average AUC per minute. Parts (a) and (b) have different scales, and hence are inter-
preted as: (a) difference in means of outcome, for a 1 kg/m2 higher BMI; (b) percentage difference of outcome, for a 1 kg/m2 higher BMI. n complete
data: 43 (except postprandial n: 33; time to peak n: 32); n approximal imputed: 44 (except postprandial and time to peak n: 33); n other day imputed:
44 (except postprandial and time to peak n: 32). Meal event measures could not be calculated for some participants (e.g. because they have no
recorded meals on included days or no peak after a recorded meal event) such that these summaries are based on a subset of our sample. Analyses
included one summary value per participant. Where a participant had measures at both pregnancy time-points this analysis used the later pregnancy
time-point. See Supplementary Figure 7 for results of our sensitivity analysis including instead the early pregnancy time-point for these participants.
Number of participants with both time-points was 11 in complete days and approximal imputed data, and 12 in other day imputed data.
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precision . As this field matures we plan to update GLU
with any additional summary variables or options (e.g.
revised thresholds for hypo-, normo- and hyper-
glycaemia) that emerge and we encourage researchers to
send feedback on the tool and suggest additions (via the
corresponding author email).
Supplementary Data
Supplementary data are available at IJE online.
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